Get the Stockscreener App
1.03
2.83%
-0.03
Estrella Immunopharma Inc stock is traded at $1.03, with a volume of 40,352.
It is down -2.83% in the last 24 hours and down -7.21% over the past month.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
See More
Previous Close:
$1.06
Open:
$1.11
24h Volume:
40,352
Relative Volume:
0.49
Market Cap:
$44.33M
Revenue:
-
Net Income/Loss:
$-13.06M
P/E Ratio:
-2.8843
EPS:
-0.3571
Net Cash Flow:
$-1.79M
1W Performance:
-8.85%
1M Performance:
-7.21%
6M Performance:
-43.09%
1Y Performance:
+7.29%
1-Day Range:
$1.00
$1.11
1-Week Range:
$1.00
$1.2097
52-Week Range:
$0.78
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
(510) 318-9098
Address
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.03 | 44.33M | 0 | -13.06M | -1.79M | -0.3571 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Estrella Immunopharma Inc Stock (ESLA) Latest News
Estrella Immunopharma Inc. (ESLA) Q1 2026 Earnings: Miss on EPS as Pre-Revenue Biotech Navigates Clinical DevelopmentStrong Earnings Momentum - newsline.com
Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Estrella Immunopharma (ESLA) Edges Higher Amid Broader Biotech SentimentWyckoff Accumulation - newsline.com
ESLAW Warrants Slide 13% as Support at $0.10 Faces Critical TestStop Hunt - newsline.com
ESLA Q1 2026 Earnings: Wider Loss Than Expected Amid Pre-Revenue Development StageEPS Revision Trend - newsline.com
ESLA Q1 2026 Earnings: EPS Misses Estimates by Wide Margin as Stock Rises 10.6%Earnings Sentiment Score - newsline.com
ESLA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-revenue Biotech Continues DevelopmentEarnings Revision Report - The Legal Advocate
Estrella Immunopharma (ESLA) Edges Lower Near Support as Biotech Sector Faces HeadwindsMutual Fund Flow - The Legal Advocate
ESLAW Surges 22.52%: Estrella Immunopharma Warrant Breaks Above SupportVolatility Surface - The Legal Advocate
Estrella Immunopharma Inc. (ESLA) Shows Modest Uptick Amid Sector StabilityLinear Regression - The Legal Advocate
Estrella Immunopharma (ESLA) sets virtual 2026 meeting to ratify auditor - Stock Titan
Estrella Immunopharma Warrant (ESLAW) Surges 18.85% to $0.10, Faces Key Resistance at $0.11Volume Breadth - The Legal Advocate
Estrella Immunopharma (ESLA) Q1 2026 Earnings: Wider-Than-Expected Loss Triggers Modest Stock GainLow Growth Earnings - Newser
ESLA Q1 2026 Earnings: Wider-Than-Expected Loss and No Revenue Highlight Development-Stage Challenges - newsline.com
Estrella Immunopharma (ESLA) Q1 2026 Earnings Slump: EPS Falls Short of $-0.18 TargetHigh Interest Stocks - Newser
Estrella Immunopharma, Inc. 2026 Q1 Financial Report: Key Financials, Related Party Transactions, and R&D Update - Minichart
Estrella Immunopharma (ESLA) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Growth Rate - Newser
Estrella Immunopharma, Inc. 1Q 2026: Net income $(2.29M), EPS $(0.05) — 10-Q Summary - TradingView
Estrella Immunopharma (ESLA) Stock Analysis: Falls -6.22%, Watching $1.07 2026-05-15Popular Market Picks - newser.com
[SCHEDULE 13G] Estrella Immunopharma, Inc. Passive Investment Disclosure (>5%) - Stock Titan
TradingKey - TradingKey
The quiet positioning of Estrella (ESLAW) nobody discusses (Moonwalks) 2026-05-08Bullish Pattern - newser.com
Estrella Immunopharma (ESLA) Q1 loss deepens, EPS miss of 90.6 percent rattles investor confidence.Special Dividend Alert - The Legal Advocate
Estrella Immunopharma (ESLA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference - BioSpace
10-K/A: Annual report (Amendment) - Moomoo
Is Estrella (ESLAW) stock a safe investment |EBITDA Margin Trends - newsline.com
Eureka-led Estrella (NASDAQ: ESLA) details 59.3% control and board pay - Stock Titan
Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock - Investing.com
Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock By Investing.com - Investing.com Canada
Estrella Immunopharma (ESLA) CFO boosts stake with small share buys - Stock Titan
ESLA Estrella Immunopharma falls 3.92% after Q1 2026 EPS misses analyst forecasts by a wide 90.6% margin.Growth Phase - newser.com
Is Estrella (ESLAW) stock a good option for investors |High Volatility - newser.com
Estrella Immunopharma (ESLA) Stock: Changing Trend? (Institutional Selling) 2026-04-27News Sentiment - newsline.com
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Declines By 57.6% - MarketBeat
OneIM Acquisition Corp. (OIM) - Minichart
Estrella Immunopharma (ESLA) Management Strategy | Q1 2026: Below ExpectationsStrong Sell - Cổng thông tin điện tử tỉnh Tây Ninh
Robinson Opportunistic Income Fund's Estrella Immunopharma Inc(ESLAW) Holding History - GuruFocus
Estrella Immunopharma (ESLA) Stock Dividend Yield (Drifts Lower) 2026-04-20Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai
ESLA (Estrella Immunopharma Inc.) reports wider than expected Q1 2026 EPS loss but shares rise 13 percent in regular trading.Segment Revenue Breakdown - The Legal Advocate
Estrella Immunopharma, Inc. (ESLAW) - Minichart
Estrella Immunopharma (ESLA) Stock: Increase Exposure? (Dips) 2026-04-16Trending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La
Sectors Review: Should you buy the dip on Estrella Immunopharma Inc2026 Retail Activity & Daily Profit Maximizing Tips - baoquankhu1.vn
Published on: 2026-04-09 23:33:21 - baoquankhu1.vn
Quarterly Recap: Is Estrella Immunopharma Inc stock a good pick for beginnersQuarterly Investment Review & Safe Capital Growth Stock Tips - baoquankhu1.vn
Is Estrella Immunopharma (ESLA) Stock a Buy Now | Price at $1.88, Up 9.30%Money Flow - newsline.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Sahm
Aug Drivers: Will Estrella Immunopharma Inc benefit from current market trendsPortfolio Performance Report & Verified Technical Signals - baoquankhu1.vn
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Estrella Immunopharma Inc Stock (ESLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Xu Jiandong | Chief Financial Officer |
Sep 22 '25 |
Buy |
1.16 |
1,000 |
1,160 |
16,700 |
| Xu Jiandong | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.04 |
100 |
104 |
264,588 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):